Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 1

Conditions

Lymphoma 178Lymphoma, Large B-Cell, Diffuse 172Precursor Cell Lymphoblastic Leukemia-Lymphoma 88Lymphoma, Follicular 79Lymphoma, Non-Hodgkin 73Burkitt Lymphoma 66Hodgkin Disease 45Leukemia 44Lymphoma, Mantle-Cell 41Lymphoma, T-Cell, Peripheral 31Lymphoma, B-Cell 30Lymphoma, B-Cell, Marginal Zone 28Lymphoma, Large-Cell, Anaplastic 26Lymphoma, Large-Cell, Immunoblastic 24Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Recurrence 15Immunoblastic Lymphadenopathy 15Neoplasms 14Lymphoma, T-Cell 14Dendritic Cell Sarcoma, Interdigitating 13Waldenstrom Macroglobulinemia 9Multiple Myeloma 9Blast Crisis 8Myelodysplastic Syndromes 7Lymphoma, T-Cell, Cutaneous 7Leukemia, Biphenotypic, Acute 7Enteropathy-Associated T-Cell Lymphoma 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Neoplasms, Plasma Cell 6

Interventions

Brentuximab Vedotin 21Cyclophosphamide 17Rituximab 11fludarabine 9Mycophenolic Acid 9pirtobrutinib 7dacetuzumab 7Busulfan 7fludarabine phosphate 6Tacrolimus 6Melphalan 6Whole-Body Irradiation 5Doxorubicin 5Vincristine 4Prednisone 4Mesna 4Etoposide 4Bone Marrow Transplantation 4Bendamustine Hydrochloride 4ibrutinib 3Thiotepa 3Sirolimus 3Cyclosporine 3Bortezomib 3ponatinib 2Vorinostat 2Stem Cell Transplantation 2Rifampin 2Platelet Transfusion 2Peripheral Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Hematologic Diseases × Prednisone × Lymphoid × Clear all
NCT01777152 2021-11-30

ECHELON-2

Seagen Inc.

Phase 3 Completed
452 enrolled 16 charts 1 FDA
Lymphoid

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT02855359 2019-03-11

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Seagen Inc.

Phase 2 Terminated
24 enrolled 10 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01925612 2018-06-21

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Seagen Inc.

Phase 2 Terminated
87 enrolled 18 charts
Lymphoid

Hematologic Diseases, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01309789 2017-06-28

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

Seagen Inc.

Phase 1 Completed
39 enrolled
Lymphoid

Hematologic Diseases, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡